Grass pollen-induced seasonal allergic rhinoconjunctivitis MedDRA version: 20.0 Level: LLT Classification code 10001728 Term: Allergic rhinoconjunctivitis System Organ Class: 100000004853
Conditions
Interventions
Product Name: Pollinex Quattro Grass 1.0 mL (300 SU/mL)
Pharmaceutical Form: Suspension for injection
INN or Proposed INN: MODIFIED ALLERGEN TYROSINE-ADSORBED
Other descriptive name: GRASS POLLEN MOD
Sponsors
Allergy Therapeutics (UK) Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Understands the implications of trial participation, provided in local language in the written informed consent form (ICF), and demonstrates willingness to comply with instructions and to attend the required study visits and has signed the informed consent. 2. Male or female aged 18 to 50 years inclusive at the time of signing Informed Consent. 3. Female patients are allowed to participate in the study if they are: a. Not of childbearing potential defined as: post-menopausal (defined as at least 12 months natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause) or, b. Naturally or surgically sterile (hysterectomy; bilateral oophorectomy; bilateral tubal ligation with surgery at least 6 weeks prior to study screening) or, c. Non-pregnant, non-lactating with negative urinary pregnancy test at all visits leading up to randomization and who use at least one of the following effective contraceptive methods: i. Stable hormonal contraceptive for = 90 days prior to the study and for at least 7 days after the final injection. If < 90 days prior to the study, additional use of a double barrier method until 90 days are reached is required or, ii. Placement of an intrauterine device (IUD) or intrauterine hormone-releasing system or, iii. Successful male sterilization of the sole partner (patient must verbally confirm that appropriate post-vasectomy documentation of the absence of sperm in the ejaculate was provided after the procedure) or, iv. True abstinence, when in line with the preferred and usual lifestyle of the patient. Periodic abstinence, such as calendar, ovulation, symptothermal, post-ovulation methods, and withdrawal are not acceptable methods of contraception. 4. Good general health, as determined by the investigator, based on a medical evaluation, including medical history, physical examination, and laboratory tests. A patient with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. 5. History of moderate to severe SAR ascribed to grass (Pooideae) pollen exposure which required anti-allergic treatment for symptom control for at least two consecutive seasons prior to the study. (For definitions of moderate and severe see Table 2. 6. A positive SPT for grass pollen and histamine (wheals [longest diameter] = 3 mm) and negative SPT to the negative control (wheal diameter = 0 mm) at screening. 7. Grass specific IgE and Phl p 1/5-specific IgE (as documented by an ImmunoCAP or equivalent test) class = 2 at screening. 8. Forced expiratory volume (FEV) in 1 second (FEV1) = 80% of predicted, with an FEV1/Forced Vital Capacity (FVC) ratio = 70%. 9. Able to observe the drug washout times listed in Table 3 “Prohibited Medications/Therapies” (see Exclusion Criterion 16 and Section 5.10.2 - Prohibited Medications) prior to screening (Visit 1). The use of other medications will be permitted if they are not expected to interfere with the ability of the patient to participate in the study and provided they have been on a stable regimen (i.e. the same dosage and administration form) for 30 days prior to screening. 10. Positive CPT at Visit 1 or 1a (TSS = 6, adjusted for reference eye score), and positive CPT at Visit 2 to the same grass allergen concentration reached at Visit
Exclusion criteria
Exclusion criteria: A full list can be found in the protocol (section 4.2). A patient won't be included in this study if one or more of the following criteria apply: 1. Pregnant/lactating patient 2. Positive SPT [wheal (longest diameter) = 3 mm] at Visit 1 to: Birch/Ash/ House dust mites/ moulds/ Epithelia (see details in protocol) 3. Moderate to severe symptoms during the 3 years prior to Visit 1* to another seasonal or perennial allergen (see details in protocol) 4. Presence of any acute or chronic ocular disorder, other than allergic conjunctivitis, which could interfere with the evaluation of the CPT 5. Eye surgery within the past 6 months 6. History of autoimmune disease 7. History of other immunological disorder or other diseases (full list in protocol) that in the opinion of the investigator may pose a safety risk or compromise the interpretation of efficacy of the study treatment 8. Severe psychiatric, psychological or neurological disorder 9. Presence of moderate-severe asthma, characterised by the requirement to use of inhaled steroids at a daily dose budesonide >400 µg or equivalent, as defined in the Global Initiative for Asthma (GINA) guidelines 10. Emergency room visit or hospitalisation for asthma in the 12 months prior to Visit 1 or any history of a life-threatening asthma attack 11. Presence of non-atopic rhinitis/rhino-sinusitis (with or without polyps) 12. Nasal surgery (details in protocol) in the 8 weeks prior to Visit 1 13. Active tuberculosis 14. Presence of any skin conditions (skin abnormalities, tattoos etc.), interfering with the interpretation of the SPT results 15. Current diagnosis of type I diabetes. Patients with type II diabetes will be enrolled at the discretion of the investigator 16. History of allergen-SIT. Exception: A patient may be enrolled if all of the following points apply: a)SIT ended at least 5 years prior to Visit 1 b)At least one full annual course of SIT was completed and c)Successful effect on symptom control was observed for at least 1 pollen season after treatment 17. Treatment with a preparation containing MPL within 6 months prior to Visit 1 18. Any acute infection (incl. upper respiratory tract infections within 14 days of Visit 2, which may pose a safety risk 19. Clinical history of severe/life-threatening anaphylactic reactions to foods, insect venom, exercise, drugs or idiopathic anaphylaxis, or physical exercise 20. Clinical history of any allergy, hypersensitivity to or intolerance of the excipients of the study medication 21. Tyrosine metabolism disorders, esp. tyrosinemia and alkaptonuria 22. Inability to adhere to the washout periods listed in Section 5.10.2 with respect to Visit 1 and Visit 2, and to refrain from using the medications indicated from Visit 2 until after completion of Visit 8 23. Inability to receive epinephrine therapy 24. ß-blocker medication, including eye drops, for any indication 25. Current treatment with angiotensin converting enzyme (ACE) inhibitors 26. Any previous or current therapy with anti-IgE therapy 27. Completed/ongoing long-term treatment with tranquilisers or psychoactive drugs 28. All vaccinations administered 14 days or less prior to randomisation or any planned vaccinations during the treatment period. Emergency vaccinations can be administered at any time 29. Current or past therapy (within previous 5 years) with immunosuppressant drugs or immunomodulatory biologics 30. Clinical history of drug/alcohol abuse interferi
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of this study is to evaluate the dose-response of Pollinex Quattro Grass 1.0 mL in patients with grass pollen-induced rhinoconjunctivitis.;Secondary Objective: The secondary objective of this study is to evaluate the safety and tolerability of different doses of Pollinex Quattro Grass 1.0 mL in patients with grass pollen-induced rhinoconjunctivitis.;Primary end point(s): The primary efficacy endpoint is the post-treatment TSS following CPT.;Timepoint(s) of evaluation of this end point: Day 81 to 89 depending on visit 2 day | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Efficacy: The secondary efficacy endpoints are: 1. Change from baseline to post-treatment TSS following CPT. 2. Number of additional allergen concentration steps required to elicit a positive CPT (i.e. TSS = 6, adjusted for reference eye score) post-treatment. 3. Change in total IgE, specific IgE and IgG4, and specific IgE/total IgE ratio between screening and post-treatment;Timepoint(s) of evaluation of this end point: Day 81 to 89 depending on visit 2 day | — |
Countries
Austria, Germany, Poland
Contacts
Public ContactClinical Research Management
Bencard Allergie GmbH
Outcome results
None listed